血管内皮生长因子B(VEGFB)多克隆抗体
Polyclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB)
VEGF-B; VEGFL; VRF; VEGF-Related Factor
- 编号PAA144Bo02
- 物种Bos taurus; Bovine (Cattle,牛) 相同的名称,不同的物种。
- 来源多抗制备
- 宿主兔
- 效价-
- Ig类型 IgG
- 纯化方式抗原特异性亲和纯化
- 标记物无标记物
- 免疫原 RPA144Bo02-血管内皮生长因子B(VEGFB)重组蛋白
- 缓冲液成份0.01M 磷酸盐缓冲液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性状液体
- 浓度0.5mg/ml
- 且适物种-
- 应用WB; IHC; ICC; IP.
如果抗体需用于流式细胞术,请参见流式抗体。 - 下载 英文说明书 中文说明书
- 规格 20µl100µl 200µl 1ml 10ml
- 价格 ¥ 680 ¥ 1588 ¥ 2268 ¥ 5670 ¥ 22680
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
该抗体是针对VEGFB的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别VEGFB。
用法
Western blotting: 0.5-2µg/mL
Immunohistochemistry: 5-20µg/mL
Immunocytochemistry: 5-20µg/mL
Optimal working dilutions must be determined by end user.
储存
经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
赠品
增值服务
相关产品
编号 | 适用物种:Bos taurus; Bovine (Cattle,牛) | 应用(仅供研究使用,不用于临床诊断!) |
RPA144Bo02 | 血管内皮生长因子B(VEGFB)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA144Bo01 | 血管内皮生长因子B(VEGFB)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA144Bo01 | 血管内皮生长因子B(VEGFB)多克隆抗体 | WB; IHC; ICC; IP. |
PAA144Bo02 | 血管内皮生长因子B(VEGFB)多克隆抗体 | WB; IHC; ICC; IP. |
参考文献
杂志 | 参考文献 |
International Journal of Cardiology | Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. [PubMed: 22459379] |
Applied Sciences-Basel | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study [pubmed:29099033] |
Journal of Endocrinological Investigation | Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell [10.1007/s40618-017-0677-z] |
EXCLI Journal | Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction [] |
Cancer Chemother Pharmacol | Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors [34164713] |
留言咨询